Get the 40 Page Workbook “A Guide to High-Risk, High-Reward Investing in Revolutionary Technologies” https://felixfriends.org/moonshot
4 extracted signals · 4 resolved · 0 still active
Felix & Friends (Goat Academy)18 Aug 2025, 23:00 UTC
AI-generated source summary
This video provides fundamental analysis on five stocks under $50, each presenting a moonshot opportunity. The speaker highlights Rocket Lab, ticker RKLB, suggesting it could 10x due to successful launches and upcoming Neutron rocket launch by Q4 2025 at the fraction of spacex valuation. AST SpaceMobile, ticker ASTS, has partnerships. Viking Therapeutics, ticker VKTX, and its potential obesity cure with oral data expected in October-November. Beam Therapeutics, ticker BEAM, at $18 is working on gene-based cure. The last recommendation is Jumia Technology, ticker JMIA, taking place in Africa.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
4 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from Felix & Friends (Goat Academy)
Global Currency RESET Is Here Here's How I'm Investing NOW
US Panic: Korea's AI Bubble Just Exploded
THEY are preparing for $30,000 Gold - Here’s Why That Should Scare You
If You Missed Palantir or Nvidia. This is Even Bigger.
Why Your Portfolio Is Broken (And You Won't Know Until end of July)
The UNTHINKABLE is About to Happen to Stocks
Felix & Friends (Goat Academy)
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.